GLP-1 drugs, commonly used to treat diabetes and obesity, may be linked to a reduced risk of cancer progression, according to new research scheduled to be presented at the American Society of Clinical Oncology's annual meeting next week.

The findings suggest these medications, which include popular drugs like Ozempic and Wegovy, could have benefits beyond their established uses for blood sugar control and weight management. GLP-1 receptor agonists work by mimicking hormones that regulate blood sugar and slow digestion.

The research represents part of growing scientific interest in understanding the broader health effects of GLP-1 medications, which have gained widespread attention in recent years for their effectiveness in treating obesity and Type 2 diabetes.

Details of the study methodology, sample size, and specific cancer types examined are expected to be released when the research is formally presented at the oncology conference. The American Society of Clinical Oncology's annual meeting is one of the most prominent gatherings for cancer research professionals.

The potential cancer-related benefits would add to an expanding list of health effects researchers are studying in connection with GLP-1 drugs, including their impacts on cardiovascular health and other conditions beyond diabetes and obesity management.